Home Featured Page 283

Featured

Latest

Transcend Posts Positive Phase 2 Data from Methylone for PTSD Program

Pα+ Psychedelic Bulletin #192: Psychedelic Safety; Compass’ Lacklustre Long-Term Data; LSD Microdosing No Better than Placebo in ADHD

February 2025 Psychedelic Patent Update: Terran Secures New Overlapping IP; Porta Sophia Becomes USPTO Information Source

Beyond Guinea Pigs: Ensuring Access to Psychedelic Therapies for Europeans

MindMed Files Preliminary Prospectus In Connection With Bought Deal Equity Financing

MindMed Upsizes Previously Announced Bought Deal Public Offering

MindMed Announces $50 Million Bought Deal Public Offering

MindMed Announces Successful Completion of Pre-IND Meeting with the FDA for...

MindMed Streamlines Leadership with Further Emphasis on Integrating Psychedelic Drug Development...

MindMed Announces the Start of the First-Ever Clinical Trial Combining MDMA...

MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical...

MindMed Expands Psychedelic Microdosing Division, Adds Groundbreaking Study Evaluating LSD Microdosing...

1...281 282283Page 283 of 283

Transcend Posts Positive Phase 2 Data from Methylone for PTSD Program

Pα+ Psychedelic Bulletin #192: Psychedelic Safety; Compass’ Lacklustre Long-Term Data; LSD...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Fayzan Rab – Emory University

Transcend Posts Positive Phase 2 Data from Methylone for PTSD Program

Pα+ Psychedelic Bulletin #192: Psychedelic Safety; Compass’ Lacklustre Long-Term Data; LSD Microdosing No Better than Placebo in ADHD

February 2025 Psychedelic Patent Update: Terran Secures New Overlapping IP; Porta Sophia Becomes USPTO Information Source

Beyond Guinea Pigs: Ensuring Access to Psychedelic Therapies for Europeans

MindMed Files Preliminary Prospectus In Connection With Bought Deal Equity Financing

MindMed Upsizes Previously Announced Bought Deal Public Offering

MindMed Announces $50 Million Bought Deal Public Offering

MindMed Announces Successful Completion of Pre-IND Meeting with the FDA for...

MindMed Streamlines Leadership with Further Emphasis on Integrating Psychedelic Drug Development...

MindMed Announces the Start of the First-Ever Clinical Trial Combining MDMA...

MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical...

MindMed Expands Psychedelic Microdosing Division, Adds Groundbreaking Study Evaluating LSD Microdosing...

EDITOR PICKS

Fayzan Rab – Emory University

Transcend Posts Positive Phase 2 Data from Methylone for PTSD Program

Pα+ Psychedelic Bulletin #192: Psychedelic Safety; Compass’ Lacklustre Long-Term Data; LSD...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY